menu search

GMAB / Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag
Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL. Read More
Posted: Mar 9 2022, 10:32
Author Name: Zacks Investment Research
Views: 103180

GMAB News  

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

By Market Watch
September 5, 2023

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% an more_horizontal

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

By Reuters
September 4, 2023

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-li more_horizontal

Genmab Is Down To Attractive Levels

By Seeking Alpha
August 30, 2023

Genmab Is Down To Attractive Levels

Genmab's stock is down 15% since late 2022 highs but the company and its partners continue to execute well. The approval and launch of Epkinly for the more_horizontal

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

By GlobeNewsWire
August 28, 2023

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. more_horizontal

3 Biotech Stocks You Better Be Buying on Each and Every Dip

By InvestorPlace
July 27, 2023

3 Biotech Stocks You Better Be Buying on Each and Every Dip

Biotechnology is one of the most exciting and innovative sectors in the market, offering investors the potential for high returns coupled with groundb more_horizontal

3 Biotech Stocks That AI is Loving in July

By InvestorPlace
July 12, 2023

3 Biotech Stocks That AI is Loving in July

Artificial intelligence (AI) has become an invaluable tool for investors seeking opportunities in the stock market. Its ability to analyze large amoun more_horizontal

Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)

By Seeking Alpha
June 29, 2023

Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral)

Genmab's stock has seen negative price action despite the FDA approval of its drug, Epcoritamab, for relapsed/refractory diffuse large B-cell lymphoma more_horizontal

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

By GlobeNewsWire
June 6, 2023

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will partici more_horizontal


Search within

Pages Search Results: